Shandong Pharmaceutical Glass Announces Leadership Transition in Advance, Leading Pharmaceutical Glass Bottle Enterprise Enters New Management Cycle

Title: Shandong Pharmaceutical Glass Announces Leadership Transition in Advance, Leading Pharmaceutical Glass Bottle Enterprise Enters New Management Cycle

Shandong Pharmaceutical Glass, a global frontrunner in pharmaceutical glass packaging and a Domestic leader in medium borosilicate molded vials, has declared an early leadership reshuffle, marking the start of a new management phase.

Former Chairman Hu Yonggang stepped down two and a half years ahead of his scheduled term expiration, citing age reasons. He resigned from all roles in the company, including Chairman, Director, and legal representative, and will no longer hold any position in the enterprise or its subsidiaries. During his tenure, Hu led the company in breaking overseas monopolies in medium borosilicate pharmaceutical glass tube production, advancing high-end projects like prefilled syringes, and securing the "National Manufacturing Single Champion Enterprise" title.

Zhang Jun, the company’s 55-year-old Director and General Manager, has been appointed as the interim Chairman and legal representative, with his appointment subject to formal approval at the upcoming extraordinary shareholders' meeting. Boasting over 27 years of experience at Shandong Pharmaceutical Glass, Zhang has held key positions in workshop management, R&D, and manufacturing, equipping him with extensive expertise in production operation and technical innovation.

In tandem with the top leadership change, the company adjusted the composition of its board special committees: Li Chuanlin was named Employee Representative Director and a member of the Strategy and Sustainable Development Committee, further optimizing the governance structure.

This leadership transition coincides with the ongoing equity restructuring of the company, where Sinopharm International is set to acquire a controlling stake in its parent company Luzhong Investment, which would shift the actual controller from Yiyuan County Finance Bureau to Sinopharm Group. Despite short-term pressure from a year-on-year decline in revenue and net profit in the first three quarters of 2025, the company’s core advantages—including a nearly 90% domestic market share in medium borosilicate molded vials and a complete "vial-stopper-cap" industrial chain—remain intact. The new management team is expected to steer the company through restructuring and market challenges, sustaining its leading position in the pharmaceutical glass packaging industry.